Alzheimer Scotland propose new assessment process after latest Scottish Medicines Consortium rejection of donanemab
Alzheimer Scotland has proposed a new assessment process after the Scottish Medicines Consortium reviewed further evidence on donanemab and continued to reject its use by NHS Scotland. Henry Simmonds, Alzheimer Scotland’s Chief Executive, says: “This demonstrates the urgent need for change in the system used to assess dementia drugs if we have any hope of…
